US FDA approves Lupin’s Mirabegron extended-release tablets
The product will be manufactured at Lupin’s facility in Nagpur
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Lupin
Health Canada approves Lupin’s Rymti
Rymti is available as an injectable easy-to-use pre-filled pen and a pre-filled syringe
Lupin and DKSH sign exclusive licensing and supply agreement to market five biosimilar candidates in…
According to the agreement, Lupin’s subsidiary in Philippines, Multicare Pharma, will file for marketing approval and be…
Zydus Lifesciences and Lupin recall products in US
While Zydus Lifesciences is recalling products due to failed impurities/degradation specifications, Lupin is doing it due to CGMP…
Lupin receives tentative US FDA approval for Dasatinib tablets
Dasatinib Tablets (RLD Sprycel) had estimated annual sales of $1,569 million in the US (IQVIA MAT June 2022)
Lupin receives US FDA approval for Rufinamide tablets
The product will be manufactured at Lupin’s facility in Goa
Lupin receives approval from US FDA for Meclizine Hydrochloride Tablets USP
The product will be manufactured at Lupin’s facility in Goa
Lupin gets approval from US FDA for Azilsartan Medoxomil Tablets
The product will be manufactured at Lupin’s facility in Nagpur, India.
Accenture accelerates data-driven decision making for Lupin
Accenture deployed a digital platform based on SAP S/4HANA, providing decision makers with real-time visibility into integrated…
Lupin releases Q4FY22 results
Basis the long-term outlook, the company's Board has recommended a dividend of 200 per cent